Tesamorelin

The core clinical finding for tesamorelin is consistent reduction of visceral adipose tissue (VAT) — the deep abdominal fat that wraps around internal organs and is most strongly associated with metabolic disease. Two large 26-week placebo-controlled Phase 3 trials, along with their 52-week extension phases, established that daily subcutaneous tesamorelin significantly reduced waist circumference and VAT in adults with central fat accumulation, with reductions maintained as long as treatment continued (3, 5, 6).

Notably, the effect appears selective for visceral fat: subcutaneous fat (the fat just under the skin) was not meaningfully reduced, suggesting tesamorelin works on the metabolically active deep fat rather than causing generalized fat loss (5). When treatment was discontinued in the extension studies, visceral fat gradually reaccumulated, indicating that the peptide's effects depend on continued signaling rather than producing permanent structural change (5).

More recent work has confirmed these findings hold up in the modern treatment era. A 2024 randomized double-blind trial in adults on integrase inhibitor regimens — a population not represented in the original Phase 3 work — found tesamorelin produced significant declines in visceral fat, hepatic fat, and trunk-to-appendicular fat ratio over 12 months compared to placebo (1).

Beyond reducing fat volume, tesamorelin appears to specifically lower fat content within the liver itself. The 2024 trial measured hepatic fat fraction directly using proton magnetic resonance spectroscopy and found a median 4.2% absolute reduction in liver fat over 12 months of tesamorelin treatment, compared to essentially no change on placebo (1).

This matters because liver fat — the defining feature of metabolic dysfunction-associated steatotic liver disease — is increasingly recognized as a central driver of insulin resistance and cardiometabolic risk. The mechanism likely flows from tesamorelin's stimulation of pulsatile growth hormone release, which promotes the breakdown and export of fat from the liver. The fact that liver fat dropped substantially without negative effects on blood glucose is a meaningful finding, since older approaches using direct growth hormone administration tended to worsen glycemic control (1, 5).

An interesting line of research has looked beyond how much fat tesamorelin removes to ask whether it changes the character of the fat that remains. A secondary analysis of two Phase 3 trials examined fat density on CT imaging — a marker where higher density corresponds to smaller, more metabolically healthy fat cells, and lower density indicates large, dysfunctional adipocytes characteristic of obesity-related disease (2).

Over 26 weeks, tesamorelin significantly increased the density of both visceral and subcutaneous fat compared to placebo, and these density improvements held even after statistically controlling for changes in fat volume (2). In other words, tesamorelin appears to improve fat tissue quality independently of how much fat it removes — the remaining adipocytes look healthier, not just fewer. This may help explain the metabolic benefits seen with treatment and points to effects on adipose tissue biology beyond simple lipolysis.

Tesamorelin's mechanism is distinct from direct growth hormone administration. As a GHRH analogue, it binds to receptors on the pituitary gland and stimulates the release of the body's own growth hormone in the natural pulsatile pattern, which is then converted in the liver to insulin-like growth factor 1 (IGF-1) (3, 4, 6). This preserves the negative feedback loops that normally regulate growth hormone levels — when IGF-1 rises sufficiently, it suppresses further pituitary output, which may explain why tesamorelin has shown a more favorable metabolic profile than direct recombinant growth hormone therapy.

This pathway-level approach is why tesamorelin became the first and so far only GHRH analogue approved for clinical use, with FDA approval in November 2010 specifically for HIV-associated lipodystrophy (3, 4). The same growth hormone axis that drives its visceral fat effects is also responsible for the modest IGF-1 elevations and occasional growth hormone-related side effects seen during treatment (5).

Reported side effects in the published trials are generally mild. The most common are injection-site reactions (redness, irritation) and effects associated with growth hormone signaling, including joint pain (arthralgia), headache, and peripheral edema (mild fluid retention). Serious adverse events occurred in fewer than 4% of participants across the Phase 3 program (5). Glycemic control was not meaningfully worsened in either the original trials or the more recent integrase-inhibitor study, an important finding given concerns with growth hormone therapies generally (1, 3, 5). Visceral fat reaccumulates after treatment is stopped, so effects depend on continued use (5). The body of tesamorelin evidence comes primarily from clinical trials in HIV-associated lipodystrophy, with limited data outside that population and limited long-term safety data beyond about one year of continuous use.